Better Context Better Decisions

Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.

$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Oct 25 | 2024Dexcom and Sanofi Q3 ’24 Earnings; Zepbound Label UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Oct 25 | 2024Viking Q3 ’24 Earnings; Luna Initiates AID Trial; Fable Obesity Startup; Mounjaro Denmark LaunchPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, Topics Oct 04 | 2024Elevai Files Patents For Obesity Lean Mass Preservation; Medtronic Pump RecallPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Topics Oct 03 | 2024FDA Removes Tirzepatide from Shortage ListPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Oct 02 | 2024Eversense 365 Launched in US; Kailera Launches as Obesity Biotech; Lilly Founds New $4.5B Indiana FacilityPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Oct 01 | 2024Roche Pharma Day; Rezdiffra QoL Publication; Pemvidutide Trial Enrollment Updates; NeuroBo Ph1 Obesity Readout; MannKind Afrezza DataPurchase Blast
1 2 3 4 95

Get the Latest Analysis

Stay informed and aligned with frequent updates to keep a pulse on the industry.

If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.